Dr. An Song joins 4D Molecular Therapeutics as Chief Development Officer, responsible for scientific development functions. Dr. Song brings over two decades of deep and diverse experience in BioAnalytical and Biomarker Development, Translational Medicine, Immunology, Cancer Immunotherapy, and Product Portfolio Management across a variety of therapeutic areas including oncology, autoimmune, neurology, ophthalmology and cardiovascular.
Prior to joining 4DMT, Dr. Song was Chief Scientific Officer at Immune-Onc Therapeutics, Inc, a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints. As a founding member of the Immune-Onc management team, Dr. Song led R&D, CMC, Translational Sciences and Biomarker functions and was responsible for Immune-Onc’s hematology/oncology biologic IND filings during her tenure. Dr. Song joined Immune-Onc from Genentech where, as a Senior Director in BioAnalytical Sciences, she led the Assay Development and Technology department to support the company’s large molecule portfolio from late-stage research to post-marketing. She was a member of numerous scientific review bodies within the Genentech Research and Early Development (gRED) organization and served on the Mentor Program and the Appointment and Promotion Committee. During her 16-year tenure at Genentech, Dr. Song contributed to and oversaw numerous IND/CTA and BLA/MAA regulatory filings for significant products including Rituxan®, Avastin®, Herceptin®, Lucentis®, Tecentriq® and played a significant role for the development and approval of Ocrevus®.
Dr. Song received her PhD in Biochemistry & Molecular Biology from Indiana University and completed a postdoctoral fellowship in Immunology at Stanford University, followed by an appointment of Research Assistant Professor and faculty of the Stanford Immunology Program.